Alprolix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Alprolix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising prevalence of hemophilia B, increased awareness and early diagnosis of bleeding disorders, the growing use of personalized treatments, and favorable healthcare policies that support the treatment of rare diseases.

For the forecast period, growth can be driven by the rise of personalized medicine, greater adoption of extended half-life factor therapies, a stronger emphasis on improving treatment adherence and quality of life, the expansion of healthcare infrastructure in emerging markets, and increasing awareness of bleeding disorders. Key trends in the forecast period include collaborations between pharmaceutical companies and healthcare providers, product innovations, advancements in clotting factor therapies, and enhancements in patient care through extended half-life therapies.

The growing prevalence of hemophilia B is expected to drive the expansion of the alprolix market in the coming years. Hemophilia B, also known as Christmas disease, is a rare inherited bleeding disorder caused by a deficiency or absence of clotting factor IX. The rising incidence of hemophilia B is largely attributed to improvements in diagnostic techniques, increased awareness and reporting, better healthcare systems that enable earlier detection, and the longer life expectancy of individuals with hemophilia due to advancements in treatment options. Alprolix, a long-acting recombinant clotting factor IX, is beneficial for patients with hemophilia B as it reduces bleeding episodes and the frequency of infusions by offering extended protection through its prolonged half-life, ultimately improving patients' quality of life. For example, in October 2023, a report from the World Federation of Hemophilia (WFH) revealed that, as of 2022, there were 257,146 identified hemophilia patients worldwide, including 42,203 individuals with hemophilia B. As such, the increasing prevalence of hemophilia B is a key factor driving the alprolix market.

The alprolix market has seen notable progress in recent years, fueled by a focus on innovative therapies to address unmet medical needs in hemophilia B treatment. One of the promising developments is Factor IX gene therapy, which involves delivering a functional copy of the FIX gene using adeno-associated virus (AAV) vectors. This approach aims to provide long-term clotting factor production, reduce bleeding episodes, and potentially offer a one-time treatment for hemophilia B. For instance, in April 2024, Pfizer Inc. received approval from the U.S. FDA for Beqveztm (fidanacogene elaparvovec), a gene therapy designed to treat hemophilia B. This approval represents a significant breakthrough in hemophilia treatment, offering the potential for a one-time therapy that could eliminate or reduce the need for routine clotting factor infusions. The therapy works by delivering a functional copy of the recombinant clotting factor IX gene, which provides sustained levels of factor IX and helps prevent bleeding episodes. Clinical trials have demonstrated durable efficacy and a favorable safety profile for patients with severe or moderately severe hemophilia B.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Emergent BioSolutions for an undisclosed sum. This acquisition will allow Bora Pharma to expand its capabilities in the biotechnology and pharmaceutical sectors, particularly by enhancing its contract development and manufacturing services (CDMO) portfolio. Emergent BioSolutions, a U.S.-based company, is known for offering recombinant coagulation factor IX-based treatments.

Key player operating in the alprolix market is Sanofi.

North America was the largest region in the alprolix market in 2024. The regions covered in alprolix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alprolix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alprolix is a recombinant coagulation factor IX Fc fusion protein designed to treat and prevent bleeding episodes in individuals with hemophilia B. It works by substituting the missing factor IX, promoting proper blood clotting, and has an extended half-life, which minimizes the need for frequent infusions to maintain effective treatment.

The alprolix market primarily consists of recombinant coagulation factor IX and plasma-derived coagulation factor IX. Recombinant factor IX is a bioengineered protein used to replace the deficient or dysfunctional factor IX in hemophilia B patients, helping to prevent excessive bleeding and support normal clotting. These products are available in different formulations, including injectable solutions and reconstitution powders. They are applied in treatments for hemophilia B, prophylaxis, and surgeries and are distributed through hospitals, specialty clinics, and online pharmacies.

The alprolix market research report is one of a series of new reports that provides alprolix market statistics, including alprolix industry global market size, regional shares, competitors with a alprolix market share, detailed alprolix market segments, market trends, and opportunities, and any further data you may need to thrive in the alprolix industry. This alprolix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alprolix market consists of sales of alprolix 250IU and alprolix 500 IU. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.